改良FLAG方案治疗难治性急性髓系白血病的临床观察  

Modified FLAG regimen in treatment for refractory acute myeloid leukemia

作　　者：张开峰[1,2] 韦菊英[1] 肖峰[1] 孟海涛[1] 钱文斌[1] 

机构地区：[1]浙江大学医学院附属第一医院血液科,杭州310003 [2]嵊州市人民医院血液科

出　　处：《浙江医学》2014年第3期228-230,共3页Zhejiang Medical Journal

基　　金：浙江省卫生厅课题资助项目(2012KYA069)

摘　　要：目的探讨阿糖胞苷(Ara-C)联合氟达拉滨(Flu)组成的改良FLAG方案治疗难治性急性髓系白血病(AML)患者的疗效及安全性。方法采用改良FLAG方案治疗难治性AML患者14例,其中原发难治性AML8例,复发难治性AML6例。具体方案为氟达拉滨(Flu)30mg/(m^2·d),静脉滴注,d1~5;阿糖胞苷(Ara-C)1g/(m^2·d),静脉滴注,d1~5;粒细胞集落刺激因子(G-CSF)5μg/(kg·d),皮下注射,d0~5。结果治疗1个疗程后,14例患者中7例获得完全缓解(C R),CR率50%;2例部分缓解(PR),PR率14 3%;5例未缓解(NR);总有效率(CR+PR)为64.3%。无一例治疗相关性死亡。结论改良FLAG方案是治疗难治性AML的有效方案,且安全性良好。Objective To investigate the efficacy and safety of modified FLAG regimen in treatment of refractory acute myeloid leukemia （AML）. Methods Fourteen patients with refractory AML, including 8 cases of primary refractory AML and 6 cases of relapsed refractory AML, were treated with modified FLAG regimen consisting of fludarabine （Flu） 30mg/ （m^2·d）, d1-5, cytarabine （Ara- C）1g/ （m^2·d）, d1-5, granulocyte colony- stimulating factor （G- CSF） 5μg/ （kg·d）, d0-5. Results There were 7 cases of complete remission（CR）, 2 cases of partial remission（PR） and 5 patients had no response（NR） in this series, with a CR rate of 50.0% and an overal response rate of 64.3%. Conclusion The modified FLAG regimen is safe and effective for treatment of refractory AML.

关 键 词：急性髓系白血病 难治性 FLAG方案 

分 类 号：R733.71[医药卫生—肿瘤]